Quince Therapeutics, Inc. (QNCX)
Largest Insider Buys in Sector
QNCX Stock Price History Chart
QNCX Stock Performance
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August …
Insider Activity of Quince Therapeutics, Inc.
Over the last 12 months, insiders at Quince Therapeutics, Inc. have bought $330,905 and sold $0 worth of Quince Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Quince Therapeutics, Inc. have bought $656,733 and sold $1,834 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lamond David (director) — $167,913. Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) — $107,375. Ryan Charles S. (PRESIDENT) — $62,903.
The last purchase of 77,000 shares for transaction amount of $53,900 was made by Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) on 2024‑08‑30.
List of Insider Buy and Sell Transactions, Quince Therapeutics, Inc.
| 2024-08-30 | CEO AND CHIEF MEDICAL OFFICER | 77,000 0.1802% | $0.70 | $53,900 | +14.33% | |||
| 2024-08-29 | CEO AND CHIEF MEDICAL OFFICER | 77,500 0.1782% | $0.69 | $53,475 | +13.84% | |||
| 2024-08-21 | CHIEF BUSINESS OFFICER AND COO | 30,845 0.0698% | $0.63 | $19,337 | +21.09% | |||
| 2024-08-20 | CHIEF BUSINESS OFFICER AND COO | 5,924 0.0136% | $0.60 | $3,579 | +27.05% | |||
| 2024-08-20 | PRESIDENT | 48,387 0.1191% | $0.65 | $31,452 | +27.05% | |||
| 2024-08-19 | CHIEF BUSINESS OFFICER AND COO | 2,155 0.0047% | $0.58 | $1,250 | +26.89% | |||
| 2023-12-14 | director | 22,627 0.0528% | $1.04 | $23,532 | -1.92% | |||
| 2023-12-13 | director | 22,627 0.0528% | $1.00 | $22,627 | +2.53% | |||
| 2023-12-12 | director | 22,627 0.0544% | $1.02 | $23,074 | +2.00% | |||
| 2023-12-07 | director | 19,123 0.0446% | $1.01 | $19,314 | 0.00% | |||
| 2023-12-06 | director | 19,123 0.0455% | $1.02 | $19,505 | +1.00% | |||
| 2023-12-05 | director | 19,123 0.0466% | $1.01 | $19,314 | +2.85% | |||
| 2023-12-01 | director | 14,378 0.033% | $0.94 | $13,515 | +5.39% | |||
| 2023-11-30 | director | 14,378 0.035% | $0.90 | $12,940 | +16.01% | |||
| 2023-11-29 | director | 14,378 0.035% | $0.98 | $14,090 | +6.37% | |||
| 2023-08-31 | director | 41,026 0.1136% | $1.32 | $54,154 | -21.37% | |||
| 2023-08-30 | director | 41,026 0.1145% | $1.31 | $53,744 | -19.77% | |||
| 2023-08-17 | director | 24,766 0.0684% | $1.29 | $31,948 | -17.32% | |||
| 2023-08-16 | director | 117,348 0.323% | $1.29 | $151,379 | -18.22% | |||
| 2023-08-15 | director | 107,886 0.3087% | $1.32 | $142,410 | -16.54% |
Insider Historical Profitability
| Lamond David | director | 2347545 5.3351% | $2.03 | 14 | 0 | |
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER | 843941 1.918% | $2.03 | 4 | 0 | |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO | 296540 0.6739% | $2.03 | 4 | 0 | |
| Ryan Charles S. | PRESIDENT | 122461 0.2783% | $2.03 | 1 | 0 | |
| EPIQ Capital Group, LLC | 2860967 6.502% | $2.03 | 10 | 0 | +23.94% |
Institutional Investor Ownership
| Tang Capital Management, LLC | $3.12M | 6.82 | 2.95M | -8.46% | -$288,688.87 | 0.01 | |
| The Vanguard Group | $1.2M | 2.62 | 1.13M | +16.44% | +$169,312.77 | <0.0001 | |
| EPIQ Capital Group | $896,519.00 | 1.96 | 845,773 | -2.8% | -$25,821.59 | 0.36 | |
| Renaissance Technologies | $551,000.00 | 1.2 | 520,100 | +13.39% | +$65,069.06 | <0.01 | |
| BlackRock | $352,010.00 | 0.77 | 332,086 | -1.05% | -$3,729.07 | <0.0001 |